Amgen Inc vs. Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc. Common Stock (EIKN) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| AMGN | EIKN | |
|---|---|---|
| Market Cap | $240.11 billion | $593.65 million |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | — |
AMGN leads on 1 of 1 size & scale factors.
Valuation
| AMGN | EIKN | |
|---|---|---|
| P/E Ratio | 27.15 | — |
| Price / Book | 20.54 | 1.27 |
| Price / Sales | 6.30 | — |
EIKN leads on 1 of 1 valuation factors.
Profitability
| AMGN | EIKN | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | — |
AMGN and EIKN split the profitability factors evenly.
Dividend
| AMGN | EIKN | |
|---|---|---|
| Dividend Yield | 2.31% | — |
| Payout Ratio | 62.61 | — |
AMGN and EIKN split the dividend factors evenly.
Risk & Sentiment
| AMGN | EIKN | |
|---|---|---|
| Short Interest | 1.66% | 1.60% |
EIKN leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, EIKN overview, EIKN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.